Kansai Medical University Hospital administers first patient dose of DS1025 in Global Phase 1 Clinical Trial Sponsored by Daiichi Sankyo

Summary

First patient worldwide to be dosed with investigational DS1025, a potential first-in-class CD25 directed antibody drug conjugate being evaluated in patients with advanced solid tumors OSAKA, Japan, Oct. 19, 2026 /PRNewswir...